866-997-4948(US-Canada Toll Free)

Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Dec 2013

Category :

Oncology

No. of Pages : 74 Pages


Global Markets Directs, \'Gastroesophageal (GE) Junction Carcinomas Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Gastroesophageal (GE) Junction Carcinomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gastroesophageal (GE) Junction Carcinomas. Gastroesophageal (GE) Junction Carcinomas Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Gastroesophageal (GE) Junction Carcinomas.
  • A review of the Gastroesophageal (GE) Junction Carcinomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Gastroesophageal (GE) Junction Carcinomas pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Gastroesophageal (GE) Junction Carcinomas.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Gastroesophageal (GE) Junction Carcinomas pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Gastroesophageal (GE) Junction Carcinomas Overview 6
Therapeutics Development 7
Pipeline Products for Gastroesophageal (GE) Junction Carcinomas - Overview 7
Pipeline Products for Gastroesophageal (GE) Junction Carcinomas - Comparative Analysis 8
Gastroesophageal (GE) Junction Carcinomas - Therapeutics under Development by Companies 9
Gastroesophageal (GE) Junction Carcinomas - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Gastroesophageal (GE) Junction Carcinomas - Products under Development by Companies 13
Gastroesophageal (GE) Junction Carcinomas - Companies Involved in Therapeutics Development 14
Bristol-Myers Squibb Company 14
F. Hoffmann-La Roche Ltd. 15
Amgen Inc. 16
AstraZeneca PLC 17
MedImmune, LLC 18
Millennium Pharmaceuticals, Inc. 19
Merrimack Pharmaceuticals, Inc. 20
Aslan Pharmaceuticals Pte. Ltd. 21
Gastroesophageal (GE) Junction Carcinomas - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 26
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Assessment by Therapeutic Class 33
Drug Profiles 35
pertuzumab - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
onartuzumab - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
olaparib - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
ipilimumab - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
trebananib - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
alisertib - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
varlitinib - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
MM-111 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
MEDI-4736 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Gastroesophageal (GE) Junction Carcinomas - Recent Pipeline Updates 57
Gastroesophageal (GE) Junction Carcinomas - Dormant Projects 69
Gastroesophageal (GE) Junction Carcinomas - Discontinued Products 70
Gastroesophageal (GE) Junction Carcinomas - Product Development Milestones 71
Featured News & Press Releases 71
May 16, 2012: Amgen Presents Results From Exploratory Biomarker Analysis Of Rilotumumab 71
Feb 06, 2012: Aslan Pharma Receives KFDA And IRB Grants Approval To Initiate Phase IIa Study Of ASLAN001 At Seoul National University 72

Appendix 73
Methodology 73
Coverage 73
Secondary Research 73
Primary Research 73
Expert Panel Validation 73
Contact Us 74
Disclaimer 74

List of Table


Number of Products under Development for Gastroesophageal (GE) Junction Carcinomas, H2 2013 7
Number of Products under Development for Gastroesophageal (GE) Junction Carcinomas - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 10
Comparative Analysis by Late Stage Development, H2 2013 11
Comparative Analysis by Clinical Stage Development, H2 2013 12
Products under Development by Companies, H2 2013 13
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Bristol-Myers Squibb Company, H2 2013 14
Gastroesophageal (GE) Junction Carcinomas - Pipeline by F. Hoffmann-La Roche Ltd., H2 2013 15
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Amgen Inc., H2 2013 16
Gastroesophageal (GE) Junction Carcinomas - Pipeline by AstraZeneca PLC, H2 2013 17
Gastroesophageal (GE) Junction Carcinomas - Pipeline by MedImmune, LLC, H2 2013 18
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Millennium Pharmaceuticals, Inc., H2 2013 19
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2013 20
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H2 2013 21
Assessment by Monotherapy Products, H2 2013 22
Number of Products by Stage and Target, H2 2013 25
Number of Products by Stage and Mechanism of Action, H2 2013 28
Number of Products by Stage and Route of Administration, H2 2013 30
Number of Products by Stage and Molecule Type, H2 2013 32
Number of Products by Stage and Therapeutic Class, H2 2013 34
Gastroesophageal (GE) Junction Carcinomas Therapeutics - Recent Pipeline Updates, H2 2013 57
Gastroesophageal (GE) Junction Carcinomas - Dormant Projects, H2 2013 69
Gastroesophageal (GE) Junction Carcinomas - Discontinued Products, H2 2013 70

List of Chart


Number of Products under Development for Gastroesophageal (GE) Junction Carcinomas, H2 2013 7
Number of Products under Development for Gastroesophageal (GE) Junction Carcinomas - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Comparative Analysis by Clinical Stage Development, H2 2013 12
Assessment by Monotherapy Products, H2 2013 22
Number of Products by Top 10 Target, H2 2013 23
Number of Products by Stage and Top 10 Target, H2 2013 24
Number of Products by Top 10 Mechanism of Action, H2 2013 26
Number of Products by Stage and Top 10 Mechanism of Action, H2 2013 27
Number of Products by Top 10 Route of Administration, H2 2013 29
Number of Products by Stage and Top 10 Route of Administration, H2 2013 30
Number of Products by Top 10 Molecule Type, H2 2013 31
Number of Products by Stage and Top 10 Molecule Type, H2 2013 32
Number of Products by Top 10 Therapeutic Class, H2 2013 33
Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 34

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *